Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Pipeline Review, H2 2017
- GMDHC0968TDB
- Pages: 55
- August 2017
- Total Views:1115
- Region : Global
- Global Markets Direct
- Market Research Report
Details
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Pipeline Review, H2 2017
Summary
According to the recently published report 'Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Pipeline Review, H2 2017'; Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Metabotropic glutamate receptor 2 is a protein encoded by the GRM2 gene. It is a receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. May mediate suppression of neurotransmission or may be involved in synaptogenesis or synaptic stabilization.
The report 'Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Pipeline Review, H2 2017' outlays comprehensive information on the Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 3 and 9 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Depression, Anxiety Disorders, Treatment Resistant Depression, Schizophrenia, Alzheimer's Disease, Chronic Pain, Cognitive Disorders, Epilepsy, Ischemia, Psychosis and Stroke.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)
The report reviews Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics and enlists all their major and minor projects
The report assesses Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) development landscape
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table Of Content
Scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Overview 7
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 13
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Therapeutics Assessment 15
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 18
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Companies Involved in Therapeutics Development 19
Addex Therapeutics Ltd 19
Bristol-Myers Squibb Company 20
Denovo Biopharma LLC 20
Domain Therapeutics SA 21
Eli Lilly and Company 21
Johnson & Johnson 22
Merck & Co Inc 22
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Drug Profiles 23
ADX-92639-Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
BMT-133218-Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
DT-2442-Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
JNJ-40411813-Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
JNJ-5515-Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
LSN-2535717-Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
LY-2607540-Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
LY-2969822-Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
LY-3020371-Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
LY-341495-Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
pomaglumetad methionil-Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Small Molecule to Modulate Metabotropic Glutamate Receptor 2 for Psychosis-Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Small Molecules to Antagonize mGlu2 for Anxiety and Depression-Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecules to Antagonize MGLUR2 for Cardiovascular and Central Nervous System Disorders-Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Dormant Products 40
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Discontinued Products 42
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Product Development Milestones 43
Featured News & Press Releases 43
Feb 27, 2017: Addex's ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia 43
Sep 23, 2015: Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy 43
Feb 19, 2015: Addex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death 44
Feb 07, 2014: Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder with Significant Anxiety Symptoms 44
Oct 29, 2013: Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression 45
Nov 05, 2012: Addex Reports Top-line Data From Successful Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients 46
Nov 05, 2012: Addex Therapeutics Reports Top-line Data From Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients 47
Sep 17, 2012: Addex Partner Doses First Patient In Phase II Clinical Study Of ADX71149 For Treatment Of Major Depressive Disorder Patients With Anxiety Symptoms 48
Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglumetad Methionil For Treatment Of Schizophrenia Based On Efficacy Results 49
Jul 11, 2012: Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study 49
Jun 05, 2012: Janssen To Initiate Phase II Clinical Trial Of ADX71149 For Treatment Of Major Depressive Disorder With Anxiety Symptoms 50
Mar 28, 2011: Addex Partner Starts Phase IIa Clinical Trial Of ADX71149 In Schizophrenia 50
Sep 02, 2010: Addex's mGluR2 Shows Efficacy In Alzheimer's Disease Model 52
Aug 25, 2010: Addex Partner Completes ADX71149 Phase I Program 52
Jun 24, 2009: Addex Partner Starts First-Ever Clinical Trial Of An mGluR Positive Allosteric Modulator 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55
List Of Figure
List of Figures
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Top 10 Indications, H2 2017 10
Number of Products by Mechanism of Actions, H2 2017 15
Number of Products by Stage and Mechanism of Actions, H2 2017 15
Number of Products by Stage and Route of Administration, H2 2017 17
Number of Products by Stage and Molecule Type, H2 2017 18
List Of Table
List of Tables
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indication, H2 2017 10
Number of Products under Development by Companies, H2 2017 11
Products under Development by Companies, H2 2017 12
Number of Products under Investigation by Universities/Institutes, H2 2017 13
Products under Investigation by Universities/Institutes, H2 2017 14
Number of Products by Stage and Mechanism of Actions, H2 2017 16
Number of Products by Stage and Route of Administration, H2 2017 17
Number of Products by Stage and Molecule Type, H2 2017 18
Pipeline by Addex Therapeutics Ltd, H2 2017 19
Pipeline by Bristol-Myers Squibb Company, H2 2017 20
Pipeline by Denovo Biopharma LLC, H2 2017 20
Pipeline by Domain Therapeutics SA, H2 2017 21
Pipeline by Eli Lilly and Company, H2 2017 21
Pipeline by Johnson & Johnson, H2 2017 22
Pipeline by Merck & Co Inc, H2 2017 22
Dormant Products, H2 2017 40
Dormant Products, H2 2017 (Contd..1), H2 2017 41
Discontinued Products, H2 2017 42
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Therapeutic Products under Development, Key Players in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Therapeutics, Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline Overview, Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline, Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline Assessment
Companies
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Therapeutic Products under Development, Key Players in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Therapeutics, Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline Overview, Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline, Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline Assessment
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Pipeline Review, H2 2017
Summary
According to the recently published report 'Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Pipeline Review, H2 2017'; Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Metabotropic glutamate receptor 2 is a protein encoded by the GRM2 gene. It is a receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. May mediate suppression of neurotransmission or may be involved in synaptogenesis or synaptic stabilization.
The report 'Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Pipeline Review, H2 2017' outlays comprehensive information on the Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 3 and 9 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Depression, Anxiety Disorders, Treatment Resistant Depression, Schizophrenia, Alzheimer's Disease, Chronic Pain, Cognitive Disorders, Epilepsy, Ischemia, Psychosis and Stroke.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)
The report reviews Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics and enlists all their major and minor projects
The report assesses Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) development landscape
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Overview 7
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 13
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Therapeutics Assessment 15
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 18
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Companies Involved in Therapeutics Development 19
Addex Therapeutics Ltd 19
Bristol-Myers Squibb Company 20
Denovo Biopharma LLC 20
Domain Therapeutics SA 21
Eli Lilly and Company 21
Johnson & Johnson 22
Merck & Co Inc 22
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Drug Profiles 23
ADX-92639-Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
BMT-133218-Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
DT-2442-Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
JNJ-40411813-Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
JNJ-5515-Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
LSN-2535717-Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
LY-2607540-Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
LY-2969822-Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
LY-3020371-Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
LY-341495-Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
pomaglumetad methionil-Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Small Molecule to Modulate Metabotropic Glutamate Receptor 2 for Psychosis-Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Small Molecules to Antagonize mGlu2 for Anxiety and Depression-Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecules to Antagonize MGLUR2 for Cardiovascular and Central Nervous System Disorders-Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Dormant Products 40
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Discontinued Products 42
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)-Product Development Milestones 43
Featured News & Press Releases 43
Feb 27, 2017: Addex's ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia 43
Sep 23, 2015: Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy 43
Feb 19, 2015: Addex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death 44
Feb 07, 2014: Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder with Significant Anxiety Symptoms 44
Oct 29, 2013: Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression 45
Nov 05, 2012: Addex Reports Top-line Data From Successful Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients 46
Nov 05, 2012: Addex Therapeutics Reports Top-line Data From Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients 47
Sep 17, 2012: Addex Partner Doses First Patient In Phase II Clinical Study Of ADX71149 For Treatment Of Major Depressive Disorder Patients With Anxiety Symptoms 48
Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglumetad Methionil For Treatment Of Schizophrenia Based On Efficacy Results 49
Jul 11, 2012: Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study 49
Jun 05, 2012: Janssen To Initiate Phase II Clinical Trial Of ADX71149 For Treatment Of Major Depressive Disorder With Anxiety Symptoms 50
Mar 28, 2011: Addex Partner Starts Phase IIa Clinical Trial Of ADX71149 In Schizophrenia 50
Sep 02, 2010: Addex's mGluR2 Shows Efficacy In Alzheimer's Disease Model 52
Aug 25, 2010: Addex Partner Completes ADX71149 Phase I Program 52
Jun 24, 2009: Addex Partner Starts First-Ever Clinical Trial Of An mGluR Positive Allosteric Modulator 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55
List Of Figure
List of Figures
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Top 10 Indications, H2 2017 10
Number of Products by Mechanism of Actions, H2 2017 15
Number of Products by Stage and Mechanism of Actions, H2 2017 15
Number of Products by Stage and Route of Administration, H2 2017 17
Number of Products by Stage and Molecule Type, H2 2017 18
List Of Table
List of Tables
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indication, H2 2017 10
Number of Products under Development by Companies, H2 2017 11
Products under Development by Companies, H2 2017 12
Number of Products under Investigation by Universities/Institutes, H2 2017 13
Products under Investigation by Universities/Institutes, H2 2017 14
Number of Products by Stage and Mechanism of Actions, H2 2017 16
Number of Products by Stage and Route of Administration, H2 2017 17
Number of Products by Stage and Molecule Type, H2 2017 18
Pipeline by Addex Therapeutics Ltd, H2 2017 19
Pipeline by Bristol-Myers Squibb Company, H2 2017 20
Pipeline by Denovo Biopharma LLC, H2 2017 20
Pipeline by Domain Therapeutics SA, H2 2017 21
Pipeline by Eli Lilly and Company, H2 2017 21
Pipeline by Johnson & Johnson, H2 2017 22
Pipeline by Merck & Co Inc, H2 2017 22
Dormant Products, H2 2017 40
Dormant Products, H2 2017 (Contd..1), H2 2017 41
Discontinued Products, H2 2017 42
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Therapeutic Products under Development, Key Players in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Therapeutics, Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline Overview, Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline, Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline Assessment
Companies
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Therapeutic Products under Development, Key Players in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Therapeutics, Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline Overview, Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline, Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) Pipeline Assessment
: +91 98100 26150 
Related Reports
Page Excel Document | 
July 2020
Page 5 | July 2020
Page 5 | July 2020
Page 5 | July 2020
Page 5 | July 2020